TRIM33 and dermatomyositis: There is additional heterogeneity within this anti–TIF1-γ–positive group, and several subgroups are apparent: (a) patients who develop a cancer within 1 year of DM onset, (b) patients who do not manifest with cancer until more than 1 year after DM diagnosis, and (c) patients who never develop a cancer (6–9).